Influence of different intravenous lipid emulsions on growth, development and laboratory and clinical outcomes in hospitalised paediatric patients: A systematic review

Edward, Roy Rosshan; Innes, Jacqueline K.; Marino, Luise V.; Calder, Philip C.

doi:10.1016/j.clnu.2017.07.003

Cited by 17 publications

(12 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of OO/SO as lipid source for IF patients was based on previous studies establishing its safety and efficacy. 41,42 However, OO/SO contains a moderate amount of EFAs (LA 18%, ALA 2.5%), and when given in low amounts, EFA provision may remain inadequate. In 2009, our hospital established multidisciplinary SBS care protocols with excellent treatment results.…”

Section: Discussionmentioning

confidence: 99%

Children With Intestinal Failure Undergoing Intestinal Rehabilitation Are at Risk for Essential Fatty Acid Deficiency

Gunnar

Lumia

Pakarinen

et al. 2018

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Children With Intestinal Failure Undergoing Intestinal Rehabilitation Are at Risk for Essential Fatty Acid Deficiency

Gunnar

Lumia

Pakarinen

et al. 2018

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…Most studies have reported no differences in oxidative stress markers between olive oil-based and soybean oil-based [ 20 , 38 , 40 , 43 , 59 , 60 , 61 ], MCT/LCT [ 60 , 62 , 63 ], or fish oil-based [ 64 , 65 ] ILE ( Table 3 ). Furthermore, a systematic review of studies in hospitalized pediatric patients suggested that available studies do not support one ILE over another with regard to benefits on oxidative stress [ 66 ].…”

Section: Lipid Peroxidationmentioning

confidence: 99%

“…We identified 24 studies [ 20 , 33 , 35 , 38 , 39 , 41 , 43 , 44 , 45 , 46 , 51 , 61 , 64 , 71 , 72 , 73 , 75 , 85 , 87 , 88 , 89 , 90 , 91 , 92 , 93 ] and three meta-analyses [ 66 , 81 , 83 ] that investigated the effects of olive oil-based ILE on liver function ( Table 5 ). Findings have varied across studies, and no clear pattern of effect of olive oil-based ILE on markers of liver function (sometimes called liver function tests) such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin (total or conjugated) or on biliary tract function markers such as alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) have been discerned.…”

Section: Liver Functionmentioning

confidence: 99%

Biological and Clinical Aspects of an Olive Oil-Based Lipid Emulsion—A Review

Cai¹,

Calder

Cury-Boaventura

et al. 2018

Nutrients

View full text Add to dashboard Cite

Intravenous lipid emulsions (ILEs) have been an integral component of parenteral nutrition for more than 50 years. Numerous formulations are available and are based on vegetable (soybean, olive, coconut) and animal (fish) oils. Therefore, each of these formulations has a unique fatty acid composition that offers both benefits and limitations. As clinical experience and our understanding of the effects of fatty acids on various physiological processes has grown, there is evidence to suggest that some ILEs may have benefits compared with others. Current evidence suggests that olive oil-based ILE may preserve immune, hepatobiliary, and endothelial cell function, and may reduce lipid peroxidation and plasma lipid levels. There is good evidence from a large randomized controlled study to support a benefit of olive oil-based ILE over soybean oil-based ILE on reducing infections in critically ill patients. At present there is limited evidence to demonstrate a benefit of olive oil-based ILE over other ILEs on glucose metabolism, and few data exist to demonstrate a benefit on clinical outcomes such as hospital or intensive care unit stay, duration of mechanical ventilation, or mortality. We review the current research and clinical evidence supporting the potential positive biological and clinical aspects of olive oil-based ILE and conclude that olive oil-based ILE is well tolerated and provides effective nutritional support to various PN-requiring patient populations. Olive oil-based ILE appears to support the innate immune system, is associated with fewer infections, induces less lipid peroxidation, and is not associated with increased hepatobiliary or lipid disturbances. These data would suggest that olive oil-based ILE is a valuable option in various PN-requiring patient populations.

show abstract

“…Several types of intravenous lipid emulsions (IVLE) are available for neonatal use. Recent systematic reviews have shown no statistically significant differences between IVLEs with respect to clinically important outcomes including mortality, growth, chronic lung disease, sepsis, severe ROP ≥ stage 3, and cholestasis by using any specific preparation in newborns [12][13][14] (LOE I, GOR C). The 2015 Survey revealed 67% of units in ANZ use both mixed 30% soybean oil/25% olive oil/30% medium-chain triglyceride oil/15% fish oil IVLE (SMO-Flipid [Fresenius Kabi, Australia]) and mixed 80% olive oil/20% soybean oil IVLE (ClinOleic [Baxter Healthcare, Australia]) [3].…”

Section: Lipidsmentioning

confidence: 99%

Standardised neonatal parenteral nutrition formulations – Australasian neonatal parenteral nutrition consensus update 2017

et al. 2020

View full text Add to dashboard Cite

Background: The first consensus standardised neonatal parenteral nutrition formulations were implemented in many neonatal units in Australia in 2012. The current update involving 49 units from Australia, New Zealand, Singapore, Malaysia and India was conducted between September 2015 and December 2017 with the aim to review and update the 2012 formulations and guidelines. Methods: A systematic review of available evidence for each parenteral nutrient was undertaken and new standardised formulations and guidelines were developed. Results: Five existing preterm Amino acid-Dextrose formulations have been modified and two new concentrated Amino acid-Dextrose formulations added to optimise amino acid and nutrient intake according to gestation. Organic phosphate has replaced inorganic phosphate allowing for an increase in calcium and phosphate content, and acetate reduced. Lipid emulsions are unchanged, with both SMOFlipid (Fresenius Kabi, Australia) and ClinOleic (Baxter Healthcare, Australia) preparations included. The physicochemical compatibility and stability of all formulations have been tested and confirmed. Guidelines to standardise the parenteral nutrition clinical practice across facilities have also been developed. Conclusions: The 2017 PN formulations and guidelines developed by the 2017 Neonatal Parenteral Nutrition Consensus Group offer concise and practical instructions to clinicians on how to implement current and up-to-date evidence based PN to the NICU population.

show abstract

Influence of different intravenous lipid emulsions on growth, development and laboratory and clinical outcomes in hospitalised paediatric patients: A systematic review

Cited by 17 publications

References 61 publications

Children With Intestinal Failure Undergoing Intestinal Rehabilitation Are at Risk for Essential Fatty Acid Deficiency

Children With Intestinal Failure Undergoing Intestinal Rehabilitation Are at Risk for Essential Fatty Acid Deficiency

Biological and Clinical Aspects of an Olive Oil-Based Lipid Emulsion—A Review

Standardised neonatal parenteral nutrition formulations – Australasian neonatal parenteral nutrition consensus update 2017

Contact Info

Product

Resources

About